MX2019010541A - Compuestos de imidazo-piperidina fusionada como inhibidores de jak. - Google Patents

Compuestos de imidazo-piperidina fusionada como inhibidores de jak.

Info

Publication number
MX2019010541A
MX2019010541A MX2019010541A MX2019010541A MX2019010541A MX 2019010541 A MX2019010541 A MX 2019010541A MX 2019010541 A MX2019010541 A MX 2019010541A MX 2019010541 A MX2019010541 A MX 2019010541A MX 2019010541 A MX2019010541 A MX 2019010541A
Authority
MX
Mexico
Prior art keywords
compounds
jak inhibitors
piperidine
fused imidazo
imidazo
Prior art date
Application number
MX2019010541A
Other languages
English (en)
Inventor
R Fatheree Paul
Smith Cameron
d e sullivan Steven
Jean Van Orden Lori
E L Brandt Gary
A Kleinschek Melanie
D Crater Glenn
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2019010541A publication Critical patent/MX2019010541A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los compuestos de fórmula (I): (ver fórmula I) donde las variables se definen en la memoria descriptiva, o una sal farmacéuticamente aceptable del mismo, son útiles como inhibidores de la quinasa JAK. También se proveen composiciones farmacéuticas que comprenden tales compuestos, métodos para usar tales compuestos para tratar procesos y enfermedades respiratorias, e intermediarios útiles para preparar tales compuestos.
MX2019010541A 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada como inhibidores de jak. MX2019010541A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469073P 2017-03-09 2017-03-09
PCT/US2018/021492 WO2018165395A1 (en) 2017-03-09 2018-03-08 Fused imidazo-piperidine jak inhibitors

Publications (1)

Publication Number Publication Date
MX2019010541A true MX2019010541A (es) 2019-10-21

Family

ID=61683956

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010541A MX2019010541A (es) 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
MX2019010539A MX2019010539A (es) 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010539A MX2019010539A (es) 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak.

Country Status (20)

Country Link
US (10) US10196393B2 (es)
EP (2) EP3592743A1 (es)
JP (2) JP6974487B2 (es)
KR (2) KR102526764B1 (es)
CN (2) CN110461839B (es)
AR (2) AR111242A1 (es)
AU (2) AU2018231032B2 (es)
BR (2) BR112019018648A2 (es)
CA (1) CA2997772A1 (es)
DK (1) DK3592742T3 (es)
EA (2) EA037261B1 (es)
ES (1) ES2882186T3 (es)
IL (2) IL268689B2 (es)
MX (2) MX2019010541A (es)
PH (2) PH12019501941A1 (es)
PT (1) PT3592742T (es)
SG (2) SG11201907840RA (es)
TW (2) TWI754019B (es)
WO (2) WO2018165395A1 (es)
ZA (2) ZA201905585B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3371185B1 (en) * 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US10100049B2 (en) 2015-11-03 2018-10-16 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
ES2882186T3 (es) 2017-03-09 2021-12-01 Theravance Biopharma R&D Ip Llc Inhibidores de JAK que contienen una amida heterocíclica de 4 miembros
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
BR112021004063A2 (pt) * 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
SG11202101785UA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc Process for preparing jak inhibitors and intermediates thereof
PL3837258T3 (pl) * 2018-09-04 2024-09-16 Theravance Biopharma R&D Ip, Llc Amidy dimetyloaminoazetydyny jako inhibitory jak
EP3853229A1 (en) * 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
PT3932919T (pt) 2019-02-25 2024-07-30 Henan Medinno Pharmaceutical Tech Co Ltd Composto inibidor de jak e sua utilização
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
US11697648B2 (en) * 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
EP4071145A4 (en) * 2019-12-30 2023-04-19 Liang Lu JAK INHIBITOR COMPOUND AND ITS USE
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022178215A1 (en) * 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
CN117813298A (zh) * 2021-06-25 2024-04-02 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑吲唑化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
JP5651681B2 (ja) 2009-04-03 2015-01-14 大日本住友製薬株式会社 代謝型グルタミン酸受容体５介在障害の治療のための化合物、およびその使用方法
CA2785037C (en) 2009-12-21 2018-01-16 Samumed, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2771340B1 (en) 2011-10-25 2016-04-13 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6192839B2 (ja) 2013-12-05 2017-09-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド
WO2015173683A1 (en) 2014-05-14 2015-11-19 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
EP3865481A1 (en) 2015-11-03 2021-08-18 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3371185B1 (en) 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US10100049B2 (en) 2015-11-03 2018-10-16 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
ES2882186T3 (es) 2017-03-09 2021-12-01 Theravance Biopharma R&D Ip Llc Inhibidores de JAK que contienen una amida heterocíclica de 4 miembros
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AU2018261591B2 (en) 2017-05-01 2021-09-02 Theravance Biopharma R&D Ip, Llc Crystalline forms of a JAK inhibitor compound
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
PL3837258T3 (pl) 2018-09-04 2024-09-16 Theravance Biopharma R&D Ip, Llc Amidy dimetyloaminoazetydyny jako inhibitory jak
SG11202101785UA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc Process for preparing jak inhibitors and intermediates thereof
BR112021004063A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak

Also Published As

Publication number Publication date
JP2020510015A (ja) 2020-04-02
AR111242A1 (es) 2019-06-19
PT3592742T (pt) 2021-07-30
PH12019501941A1 (en) 2020-07-06
US20190337945A1 (en) 2019-11-07
US20190119275A1 (en) 2019-04-25
EA201992128A1 (ru) 2020-01-29
US20180258088A1 (en) 2018-09-13
IL268689B2 (en) 2023-02-01
IL268689A (en) 2019-10-31
ZA201905618B (en) 2021-05-26
US20230063643A1 (en) 2023-03-02
US10196393B2 (en) 2019-02-05
ES2882186T3 (es) 2021-12-01
US11878977B2 (en) 2024-01-23
DK3592742T3 (da) 2021-08-09
CN110382498A (zh) 2019-10-25
US10392386B2 (en) 2019-08-27
CN110382498B (zh) 2022-07-12
AU2018231035A1 (en) 2019-09-05
MX2019010539A (es) 2019-10-21
CA2997772A1 (en) 2018-09-09
TWI779016B (zh) 2022-10-01
AU2018231032A1 (en) 2019-09-05
US11254669B2 (en) 2022-02-22
JP6974487B2 (ja) 2021-12-01
US20200181141A1 (en) 2020-06-11
KR102526764B1 (ko) 2023-04-27
ZA201905585B (en) 2020-05-27
PH12019501985A1 (en) 2020-10-05
EP3592743A1 (en) 2020-01-15
US20190127371A1 (en) 2019-05-02
BR112019018649A2 (pt) 2020-04-07
AU2018231035B2 (en) 2021-09-09
EA037261B1 (ru) 2021-03-01
AU2018231032B2 (en) 2021-08-19
IL268679B (en) 2021-10-31
US11667637B2 (en) 2023-06-06
EA037748B1 (ru) 2021-05-18
US10208040B2 (en) 2019-02-19
US20220289737A1 (en) 2022-09-15
US11453668B2 (en) 2022-09-27
BR112019018648A2 (pt) 2020-06-16
EA201992126A1 (ru) 2020-02-05
TW201837037A (zh) 2018-10-16
CN110461839B (zh) 2022-08-23
SG11201907840RA (en) 2019-09-27
NZ756823A (en) 2021-04-30
KR20190127798A (ko) 2019-11-13
AR111241A1 (es) 2019-06-19
TW201840560A (zh) 2018-11-16
EP3592742B1 (en) 2021-05-19
CN110461839A (zh) 2019-11-15
US10550118B2 (en) 2020-02-04
WO2018165395A1 (en) 2018-09-13
US10519153B2 (en) 2019-12-31
SG11201907544VA (en) 2019-09-27
EP3592742A1 (en) 2020-01-15
KR102533646B1 (ko) 2023-05-17
IL268679A (en) 2019-10-31
JP2020510010A (ja) 2020-04-02
JP7134990B2 (ja) 2022-09-12
TWI754019B (zh) 2022-02-01
IL268689B (en) 2022-10-01
WO2018165392A1 (en) 2018-09-13
KR20190127796A (ko) 2019-11-13
US20180258087A1 (en) 2018-09-13
US20200216447A1 (en) 2020-07-09
US20210269436A1 (en) 2021-09-02
AU2018231032A8 (en) 2019-10-17
US10954237B2 (en) 2021-03-23

Similar Documents

Publication Publication Date Title
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
PH12018500828A1 (en) Jak kinase inhibitor compounds for treatment of respiratory disease
PH12017502050B1 (en) Naphthyridine compounds as jak kinase inhibitors
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
MX2018013191A (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MX2021002521A (es) Dimetilaminoazetidinaminas como inhibidores de jak.
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
PH12021550324A1 (en) 5 to 7 membered heterocyclic amides as jak inhibitors
SA521422152B1 (ar) Vanin مركبات عطرية غير متجانسة كمثبطات
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
PH12019502693A1 (en) Heteroaromatic compounds as vanin inhibitors
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2021006489A (es) Compuestos heteroaromaticos como inhibidores de vanina.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX2019000542A (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
EA201990686A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы